drugset
drugset / Trial / NCT06698965

Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin

NCT06698965 ↗

Phase 2 Recruiting 52 enrolled Shanghai Chest Hospital Jiangsu Simcere Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This prospective, randomized, controlled phase II study aims to evaluate the efficacy of combination therapy with Envafolimab and chemotherapy in first-line extensive stage SCLC, as well as the impact of Trilaciclib on the incidence of myelosuppression and anti-tumor effects in patients.

Timeline

Start
2024-10-13
Primary completion
2029-10-31
Completion
2029-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Trilaciclib Unknown 240 mg/m2 Intravenous
Background Carboplatin Small molecule 5 unknown Intravenous
Background Envafolimab Monoclonal antibody 300 mg Subcutaneous
Background Etoposide Small molecule 80 mg/m2 Intravenous
Background Etoposide Small molecule 100 mg/m2 Intravenous

Indications

small cell lung carcinoma